New trial data showed CagriSema led to “superior” weight loss, but at a rate much less than original expectations of 25%.

In a statement, Trotter described his experience as a child with older relatives who struggled with Type 2 diabetes. Trotter ...

Insurance companies generally cover Ozempic and Wegovy when it is prescribed for Type 2 diabetes. However, when the drugs are ...

The setback comes at a crucial time for Novo Nordisk, which had positioned CagriSema as its next-generation weight-loss ...

Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest dose of the drug lost 15.7% of their weight.

Novo Nordisk stock was down more than 8% Monday morning after the Danish drugmaker shared new data on its next-generation GLP ...

Hikma Pharmaceuticals (HKMPF) is in talks with partners across the world to prepare to sell a generic version of Ozempic and Wegovy, as patents ...

I had no idea this could happen. I wouldn’t have done it,” New Jersey-based former Mounjaro user James Norris, who is now visually impaired, told The Post ...

Despite falling hard since last summer, shares of Novo Nordisk have more than doubled the market's overall performance. The ...

The Danish company said the average weight loss was 15.7% for the new drug, CagriSema. The expectation had been about 25%.